Hématologie Myélome
IFM 2017-03
A Phase 3 Study Comparing Lenalidomide and Daratumumab;Subcutaneous Injection (R-Dara SC) vs Lenalidomide and;Dexamethasone (Rd) in Frail Subjects with Previously Untreated;Multiple Myeloma who are Ineligible for High Dose Therapy.;Protocol IFM2017-03.
Paris
FREDERIQUE KUHNOWSKI